Harmony Biosciences Holdings, Inc. (HRMY) shareholders
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,361,888 | 12.60% | 13G (passive) amendment | Sep 30, 2026 |
| Marshman Fund Trust II | 6,051,120 | 10.60% | 13G (passive) amendment | Dec 31, 2024 |
| FMR LLC Joint filing with Abigail P. Johnson (6.70%) | 3,846,972 | 6.70% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (5.40%) | 3,112,812 | 5.40% | 13G (passive) amendment | Dec 31, 2025 |
| Vanguard Portfolio Management | 2,943,383 | 5.08% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HRMY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,101,965 | 12.20% | $258.58M | +31,930 | 0.00% |
| FMR LLC | 3,574,115 | 6.14% | $130.13M | +416,476 | 0.01% |
| Vanguard Portfolio Management LLC | 2,880,489 | 4.95% | $104.88M | +166,136 | 0.00% |
| American Century Companies Inc | 2,539,512 | 4.36% | $92.46M | +434,333 | 0.04% |
| Dimensional Fund Advisors LP | 2,393,588 | 4.11% | $87.14M | +317,078 | 0.02% |
| Vanguard Capital Management LLC | 2,105,053 | 3.61% | $76.64M | +2,738 | 0.00% |
| Lsv Asset Management | 2,061,242 | 3.54% | $75.05M | +36,099 | 0.14% |
| State Street Corp | 1,859,322 | 3.19% | $67.70M | +74,960 | 0.00% |
| Armistice Capital, LLC | 1,564,000 | 2.69% | $56.95M | −60,000 | 0.70% |
| Geode Capital Management, LLC | 1,442,649 | 2.48% | $52.53M | +119,929 | 0.00% |
| Arrowstreet Capital, Limited Partnership | 1,312,550 | 2.25% | $47.79M | −69,563 | 0.02% |
| Renaissance Technologies LLC | 1,195,371 | 2.05% | $43.52M | +118,000 | 0.06% |
| Two Sigma Investments, LP | 959,136 | 1.65% | $34.92M | +225,693 | 0.03% |
| Aqr Capital Management LLC | 934,326 | 1.60% | $34.02M | +218,080 | 0.01% |
| SG Americas Securities, LLC | 882,720 | 1.52% | $32.14M | −1,135,454 | 0.02% |
| Valor Management LLC | 818,013 | 1.40% | $29.78M | +700,883 | 0.03% |
| Morgan Stanley | 733,684 | 1.26% | $26.71M | −297,334 | 0.00% |
| UBS Group AG | 602,990 | 1.04% | $21.95M | +154,999 | 0.00% |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 551,075 | 0.95% | $20.06M | −16,040 | 0.02% |
| Invesco Ltd. | 528,520 | 0.91% | $19.24M | −99,727 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 327 | 54M | 93.0% | 53 / 131 | 107 / 33 | 6M | 8M |
| Q1 2026 | 311 | 56M | 96.1% | 44 / 131 | 98 / 51 | 16M | 6M |
| Q4 2025 | 325 | 50M | 86.1% | 60 / 121 | 111 / 30 | 8M | 5M |
| Q3 2025 | 297 | 48M | 81.8% | 45 / 116 | 88 / 26 | 6M | 9M |
| Q2 2025 | 279 | 51M | 88.0% | 39 / 126 | 71 / 31 | 6M | 5M |
| Q1 2025 | 272 | 50M | 86.4% | 42 / 100 | 87 / 16 | 5M | 7M |
| Q4 2024 | 247 | 53M | 90.6% | 39 / 128 | 49 / 25 | 11M | 9M |
| Q3 2024 | 234 | 50M | 86.5% | 39 / 72 | 87 / 22 | 9M | 3M |
| Q2 2024 | 219 | 50M | 86.4% | 35 / 76 | 73 / 21 | 3M | 4M |
| Q1 2024 | 207 | 51M | 87.2% | 27 / 64 | 80 / 40 | 5M | 3M |
| Q4 2023 | 221 | 49M | 84.4% | 55 / 62 | 78 / 35 | 7M | 7M |
| Q3 2023 | 204 | 49M | 84.9% | 32 / 86 | 57 / 39 | 2M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
319 funds held HRMY in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of HRMY | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2,407,170 | 4.13% | $87.65M | 0.08% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 2,032,950 | 3.49% | $64.22M | 0.24% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,556,602 | 2.67% | $56.68M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,159,605 | 1.99% | $42.22M | 0.05% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,127,559 | 1.94% | $41.05M | 0.02% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 1,007,798 | 1.73% | $31.84M | 0.03% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 653,920 | 1.12% | $23.81M | 0.05% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 493,988 | 0.85% | $17.41M | 0.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 461,568 | 0.79% | $16.81M | 0.02% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 457,483 | 0.79% | $16.66M | 0.29% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 417,018 | 0.72% | $15.18M | 0.10% | Jun 30, 2026 |
| Invesco Pharmaceuticals ETF | 410,448 | 0.70% | $14.46M | 3.06% | Jul 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 366,197 | 0.63% | $13.33M | 0.08% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 360,552 | 0.62% | $13.13M | 0.16% | Jun 30, 2026 |
| Pacer US Small Cap Cash Cows 100 ETF | 340,511 | 0.58% | $12.00M | 0.33% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeffrey M. Dayno | PRESIDENT, CEO, Director | 13,000 | 0.02% | Jan 26, 2026 |
| Kumar Budur | CHIEF MEDICAL OFFICER | 48,967 | 0.08% | Sep 18, 2026 |
| Stephen M. Mollichella | INT PRINCIAL FINANCIAL OFFICER | 2,506 | 0.00% | Jul 22, 2026 |
| Glenn Reicin | CHIEF FINANCIAL OFFICER | – | – | May 18, 2026 |
| Adam H. Zaeske | CHIEF COMMERCIAL OFFICER | 4,327 | 0.01% | Apr 9, 2026 |
| Peter Anastasiou | CHIEF OPERATING OFFICER | – | – | Apr 6, 2026 |
| Sandip Kapadia | CHIEF FINANCIAL OFFICER | 24,521 | 0.04% | Jan 28, 2026 |
| Andrew Serafin | CHIEF STRATEGY OFFICER | 1,474 | 0.00% | Jan 26, 2026 |
| Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | 500 | 0.00% | Mar 5, 2025 |
| R. Mark Graf | Director | – | – | May 18, 2026 |
| Geno J. Germano | Director | – | – | May 18, 2026 |
| Linda M. Szyper | Director | – | – | May 18, 2026 |
| Ron M. Philip | Director | – | – | May 18, 2026 |
| Juan A. Sabater | Director | 29,497 | 0.05% | May 18, 2026 |
| Gary Sender | Director | – | – | May 18, 2026 |
| Troy A. Ignelzi | Director | – | – | Apr 6, 2026 |
| Antonio J. Gracias | Director, 10% owner | 845,336 | 1.45% | Sep 2, 2025 |
| Valor IV Pharma Holdings, LLC | 10% owner | – | – | Sep 2, 2025 |
| Equity Partners Iv L.P. Valor | 10% owner | – | – | Sep 2, 2025 |
| Management L.P. Valor | 10% owner | – | – | Sep 2, 2025 |
| Equity Partners Iv-A L.P. Valor | 10% owner | – | – | Sep 2, 2025 |
| Equity Partners Iv-B L.P. Valor | 10% owner | 6,618,033 | 11.36% | Sep 2, 2025 |
| Equity Capital IV LLC Valor | 10% owner | – | – | Sep 2, 2025 |
| Equity Associates IV L.P. Valor | 10% owner | 10,984,981 | 18.86% | Sep 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 18, 2026 | Option exercise | +25,446 | $30.27 | $770.25K | 48,967 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 18, 2026 | Sale(10b5-1 plan) | −35,852 | $43.05 | $1.54M | 13,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 18, 2026 | Option exercise | +10,406 | $30.69 | $319.36K | 23,521 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −800 | $43.00 | $34.40K | 13,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 17, 2026 | Option exercise | +400 | $30.27 | $12.11K | 13,915 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 17, 2026 | Option exercise | +400 | $30.69 | $12.28K | 13,515 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 16, 2026 | Option exercise | +900 | $30.69 | $27.62K | 14,015 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 16, 2026 | Option exercise | +900 | $30.27 | $27.24K | 14,915 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 16, 2026 | Sale(10b5-1 plan) | −1,800 | $43.01 | $77.42K | 13,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 8, 2026 | Sale(10b5-1 plan) | −4,500 | $42.25 | $190.13K | 14,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 8, 2026 | Sale(10b5-1 plan) | −1,000 | $42.79 | $42.79K | 13,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 8, 2026 | Option exercise | +12,200 | $30.69 | $374.42K | 25,315 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 8, 2026 | Sale(10b5-1 plan) | −22,954 | $43.10 | $989.32K | 13,115 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 8, 2026 | Option exercise | +10,754 | $30.27 | $325.52K | 36,069 |
| Kumar Budur CHIEF MEDICAL OFFICER | Sep 4, 2026 | Sale(10b5-1 plan) | −5,500 | $41.98 | $230.89K | 18,615 |
| Kumar Budur CHIEF MEDICAL OFFICER | May 1, 2026 | Option exercise | +18,750 | – | – | 32,997 |
| Kumar Budur CHIEF MEDICAL OFFICER | May 1, 2026 | Tax withholding | −8,882 | $31.83 | $282.71K | 24,115 |
| Adam H. Zaeske CHIEF COMMERCIAL OFFICER | Apr 7, 2026 | Tax withholding | −3,173 | $27.62 | $87.64K | 4,327 |
| Adam H. Zaeske CHIEF COMMERCIAL OFFICER | Apr 7, 2026 | Option exercise | +7,500 | – | – | 7,500 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 26, 2026 | Sale(10b5-1 plan) | −3,746 | $37.15 | $139.16K | 24,521 |
| Kumar Budur CHIEF MEDICAL OFFICER | Jan 25, 2026 | Option exercise | +2,662 | – | – | 2,662 |
| Kumar Budur CHIEF MEDICAL OFFICER | Jan 25, 2026 | Tax withholding | −1,372 | $36.82 | $50.52K | 1,290 |
| Andrew Serafin CHIEF STRATEGY OFFICER | Jan 25, 2026 | Tax withholding | −1,126 | $36.82 | $41.46K | 1,474 |
| Andrew Serafin CHIEF STRATEGY OFFICER | Jan 25, 2026 | Option exercise | +2,600 | – | – | 2,600 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 25, 2026 | Tax withholding | −2,553 | $36.82 | $94.00K | 2,172 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 25, 2026 | Option exercise | +4,725 | – | – | 4,725 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 25, 2026 | Option exercise | +13,000 | – | – | 13,000 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 25, 2026 | Tax withholding | −5,654 | $36.82 | $208.18K | 7,346 |
| Kumar Budur CHIEF MEDICAL OFFICER | Jan 24, 2026 | Tax withholding | −1,153 | $36.82 | $42.45K | 1,035 |
| Kumar Budur CHIEF MEDICAL OFFICER | Jan 24, 2026 | Option exercise | +2,188 | – | – | 2,188 |
| Andrew Serafin CHIEF STRATEGY OFFICER | Jan 24, 2026 | Tax withholding | −1,116 | $36.82 | $41.09K | 1,384 |
| Andrew Serafin CHIEF STRATEGY OFFICER | Jan 24, 2026 | Option exercise | +2,500 | – | – | 2,500 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 24, 2026 | Tax withholding | −2,239 | $36.82 | $82.44K | 1,574 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 24, 2026 | Option exercise | +3,813 | – | – | 3,813 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 24, 2026 | Tax withholding | −4,785 | $36.82 | $176.18K | 5,715 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 24, 2026 | Option exercise | +10,500 | – | – | 10,500 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 15, 2026 | Sale(10b5-1 plan) | −20,961 | $35.92 | $752.92K | 0 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Dec 12, 2025 | Option exercise | +20,000 | $8.22 | $164.40K | 20,000 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Dec 12, 2025 | Sale(10b5-1 plan) | −20,000 | $40.11 | $802.20K | 0 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Dec 12, 2025 | Sale(10b5-1 plan) | −5,933 | $40.11 | $237.97K | 0 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Dec 5, 2025 | Sale(10b5-1 plan) | −20,000 | $39.54 | $790.80K | 0 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Dec 5, 2025 | Option exercise | +20,000 | $29.03 | $580.60K | 20,000 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Nov 21, 2025 | Sale(10b5-1 plan) | −3,427 | $35.00 | $119.95K | 0 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Sep 30, 2025 | Tax withholding | −24,039 | $27.56 | $662.51K | 20,961 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Sep 30, 2025 | Option exercise | +45,000 | – | – | 45,000 |
| Juan A. Sabater Director, 10% owner | Aug 28, 2025 | Other | −6,618,033 | – | – | 0 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Aug 15, 2025 | Sale(10b5-1 plan) | −21,573 | $36.50 | $787.41K | 0 |
| Kumar Budur CHIEF MEDICAL OFFICER | May 1, 2025 | Option exercise | +18,750 | – | – | 18,750 |
| Kumar Budur CHIEF MEDICAL OFFICER | May 1, 2025 | Tax withholding | −8,869 | $29.86 | $264.83K | 9,881 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Apr 1, 2025 | Sale(10b5-1 plan) | −740 | $33.12 | $24.51K | 0 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Apr 1, 2025 | Sale(10b5-1 plan) | −6,247 | $32.48 | $202.90K | 740 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Mar 29, 2025 | Option exercise | +15,000 | – | – | 15,000 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Mar 29, 2025 | Tax withholding | −8,014 | $33.19 | $265.98K | 6,986 |
| Jeffrey Dierks CHIEF COMMERCIAL OFFICER | Mar 3, 2025 | Sale(10b5-1 plan) | −4,369 | $32.61 | $142.47K | 500 |
| Jeffrey Dierks CHIEF COMMERCIAL OFFICER | Mar 3, 2025 | Sale(10b5-1 plan) | −500 | $33.23 | $16.62K | 0 |
| Jeffrey Dierks CHIEF COMMERCIAL OFFICER | Mar 3, 2025 | Option exercise | +4,869 | $8.22 | $40.02K | 4,869 |
| Sandip Kapadia CHIEF FINANCIAL OFFICER | Jan 27, 2025 | Sale(10b5-1 plan) | −1,775 | $38.05 | $67.54K | 0 |
| Jeffrey Dierks CHIEF COMMERCIAL OFFICER | Jan 27, 2025 | Sale(10b5-1 plan) | −1,629 | $38.02 | $61.93K | 0 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 24, 2025 | Option exercise | +10,500 | – | – | 10,500 |
| Jeffrey M. Dayno PRESIDENT, CEO, Director | Jan 24, 2025 | Tax withholding | −4,567 | $38.01 | $173.59K | 5,933 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Harmony Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 47,140 shares on Sep 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kumar Budur Officer | Sep 18, 2026 | 35,852 | $1.53M | Sep 18, 2026 | Exercise of Stock Options |
| Kumar Budur Officer | Sep 17, 2026 | 800 | $33.77K | Sep 17, 2026 | Exercise of Stock Options |
| Kumar Budur Officer | Sep 16, 2026 | 1,800 | $75.91K | Sep 16, 2026 | Exercise of Stock Options |
| Kumar Budur Officer | Sep 8, 2026 | 28,454 | $1.20M | Sep 8, 2026 | Restricted Stock Units |
| Kumar Budur Officer | Sep 4, 2026 | 5,500 | $230.23K | Sep 4, 2026 | Restricted Stock Units |
| Valor IV Pharma Holdings, LLC Director | Aug 7, 2026 | 700,883 | $26.56M | Aug 7, 2026 | Private Acquisition from Issuer/Affiliate |
| Sandip Kapadia Former Officer | Jul 2, 2026 | 25,000 | $924.01K | Jul 2, 2026 | Exercise of Options Under a Registered Plan |
| Sandip Kapadia Former Officer | Jun 30, 2026 | 50,000 | $1.80M | Jun 30, 2026 | Exercise of Options Under a Registered Plan |
| Sandip Kapadia Former Officer | Jun 26, 2026 | 45,594 | $1.61M | Jun 26, 2026 | Exercise of Options Under a Registered Plan |
| Sandip Kapadia Former Officer | Jun 24, 2026 | 4,406 | $154.30K | Jun 24, 2026 | Exercise of Options Under a Registered Plan |
| Sandip Kapadia Former Officer | Jun 9, 2026 | 27,960 | $943.26K | Jun 9, 2026 | Exercise of Options Under a Registered Plan |
| Sandip Kapadia Former Officer | Jun 5, 2026 | 2,101 | $69.50K | Jun 5, 2026 | Exercise of Options Under a Registered Plan |
| Sandip Kapadia Former Officer | Jun 4, 2026 | 7,064 | $233.23K | Jun 4, 2026 | Exercise of Options Under a Registered Plan |
| Sandip Kapadia Former Officer | May 8, 2026 | 45,481 | $1.43M | May 8, 2026 | Restricted stock vesting under a registered plan |
| Sandip Kapadia Officer | Jan 26, 2026 | 3,746 | $137.93K | Jan 26, 2026 | Restricted Stock Units |
See a number that looks wrong?